Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The promises and pitfalls of RNA-interference-based therapeutics.

Castanotto D, Rossi JJ.

Nature. 2009 Jan 22;457(7228):426-33. doi: 10.1038/nature07758. Review.

2.

RNA interference in three humans.

Hare P.

Nat Biotechnol. 2010 Apr;28(4):335. doi: 10.1038/nbt0410-335. No abstract available.

PMID:
20379178
3.

RNAi mechanisms and applications.

Kim D, Rossi J.

Biotechniques. 2008 Apr;44(5):613-6. doi: 10.2144/000112792. Review.

4.

Companies in footrace to deliver RNAi.

Bouchie A.

Nat Biotechnol. 2012 Dec;30(12):1154-7. doi: 10.1038/nbt1212-1154. No abstract available.

PMID:
23222766
5.

Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.

DeVincenzo JP.

Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. doi: 10.1016/j.earlhumdev.2009.08.013. Epub 2009 Oct 14.

PMID:
19833462
6.

Innovations in siRNA research: a technology comes of age.

Hefferon KL.

Recent Pat Antiinfect Drug Discov. 2010 Nov;5(3):226-39. Review.

PMID:
20812899
7.

Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Guzman-Aranguez A, Loma P, Pintor J.

Br J Pharmacol. 2013 Oct;170(4):730-47. doi: 10.1111/bph.12330. Review.

8.

Interfering with disease: opportunities and roadblocks to harnessing RNA interference.

Lieberman J, Song E, Lee SK, Shankar P.

Trends Mol Med. 2003 Sep;9(9):397-403. Review.

PMID:
13129706
9.

Cutaneous short-interfering RNA therapy.

Geusens B, Sanders N, Prow T, Van Gele M, Lambert J.

Expert Opin Drug Deliv. 2009 Dec;6(12):1333-49. doi: 10.1517/17425240903304032. Review.

PMID:
19941411
10.

Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.

Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, Li L, Chung TK, Tang T.

Gene. 2014 Apr 1;538(2):217-27. doi: 10.1016/j.gene.2013.12.019. Epub 2014 Jan 7. Review.

PMID:
24406620
11.

Cardiovascular RNA interference therapy: the broadening tool and target spectrum.

Poller W, Tank J, Skurk C, Gast M.

Circ Res. 2013 Aug 16;113(5):588-602. doi: 10.1161/CIRCRESAHA.113.301056. Review.

12.

Silencing of disease-related genes by small interfering RNAs.

Fuchs U, Damm-Welk C, Borkhardt A.

Curr Mol Med. 2004 Aug;4(5):507-17. Review.

PMID:
15267222
13.

RNA interference in mammalian cell systems.

Lochmatter D, Mullis PE.

Horm Res Paediatr. 2011;75(1):63-9. doi: 10.1159/000322817. Epub 2011 Jan 17. Review.

PMID:
21252559
14.

RNA interference as a gene knockdown technique.

Shan G.

Int J Biochem Cell Biol. 2010 Aug;42(8):1243-51. doi: 10.1016/j.biocel.2009.04.023. Epub 2009 May 13. Review.

PMID:
19442757
15.

Molecular medicine for the brain: silencing of disease genes with RNA interference.

Davidson BL, Paulson HL.

Lancet Neurol. 2004 Mar;3(3):145-9. Review.

PMID:
14980529
16.

siRNA and miRNA for the treatment of cancer.

Jankovic R, Radulovic S, Brankovic-Magic M.

J BUON. 2009 Sep;14 Suppl 1:S43-9. Review.

PMID:
19785069
17.

RNA interference: Homing in on delivery.

Baker M.

Nature. 2010 Apr 22;464(7292):1225-8. doi: 10.1038/4641225a. No abstract available.

PMID:
20414308
18.

RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Snead NM, Rossi JJ.

Nucleic Acid Ther. 2012 Jun;22(3):139-46. doi: 10.1089/nat.2012.0361. Review.

19.

Short interfering RNA therapeutics: nanocarriers, prospects and limitations.

Mehrotra N, Tripathi RM.

IET Nanobiotechnol. 2015 Dec;9(6):386-95. doi: 10.1049/iet-nbt.2015.0018. Review.

PMID:
26647816
20.

RNAi therapeutics: an update on delivery.

Nguyen T, Menocal EM, Harborth J, Fruehauf JH.

Curr Opin Mol Ther. 2008 Apr;10(2):158-67. Review.

PMID:
18386228

Supplemental Content

Support Center